2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
Authors:
Open Access
- 1 February 2015
- journal article
- review article
- Published by Elsevier in EBioMedicine
- Vol. 2 (2) , 92-93
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014